Photothermal therapy of tumors in lymph nodes using gold nanorods and near-infrared laser light

Okuno, Tatsuki; Kato, Shigekí; Hatakeyama, Yuriko; Okajima, Junnosuke; Maruyama, Shigenao; Sakamoto, Maya; Mori, Shiro; Kodama, Tetsuya

doi:10.1016/j.jconrel.2013.10.014

Cited by 80 publications

(56 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concept is to inject drugs, before surgical resection, into upstream LNs within the dissection area, so that these drugs are delivered to downstream LNs outside the dissection area. To demonstrate proof of concept, we have developed MXH10/Mo-lpr/lpr (MXH10/Mo/lpr) inbred mice [1][2][3][4], and metastatic tumor cell lines able to grow in the mice. The phenotype of the lpr (lymphproliferation) gene is characterized by the accumulation of a large number of polyclonal CD4 -CD8 -T cells in the LNs and spleen [5]; the lpr gene is recognized as a "promoting factor" for collagen disease in MRL mice due to Fas-mediated apoptotic insufficiency, and the causative genes of collagen disease are considered to be the background genes of MRL mice [6].…”

Section: Introductionmentioning

confidence: 99%

Visualization of fluid drainage pathways in lymphatic vessels and lymph nodes using a mouse model to test a lymphatic drug delivery system

Kodama

Hatakeyama

Kato

et al. 2014

Biomed. Opt. Express

Self Cite

View full text Add to dashboard Cite

Curing/preventing micrometastasis to lymph nodes (LNs) located outside the surgically resected area is essential for improving the morbidity and mortality associated with breast cancer and head and neck cancer. However, no lymphatic therapy system exists that can deliver drugs to LNs located outside the dissection area. Here, we demonstrate proof of concept for a drug delivery system using MXH10/Mo-lpr/lpr mice that exhibit systemic lymphadenopathy, with some peripheral LNs being as large as 10 mm in diameter. We report that a fluorescent solution injected into the subiliac LN (defined as the upstream LN within the dissection area) was delivered successfully to the proper axillary LN (defined as the downstream LN outside the dissection area) through the lymphatic vessels. Our results suggest that this approach could be used before surgical resection to deliver drugs to downstream LNs outside the dissection area. We anticipate that our methodology could be applied clinically, before surgical resection, to cure/prevent micrometastasis in LNs outside the dissection area, using techniques such as ultrasound-guided internal jugular vein catheterization.

show abstract

Section: Introductionmentioning

confidence: 99%

Visualization of fluid drainage pathways in lymphatic vessels and lymph nodes using a mouse model to test a lymphatic drug delivery system

Kodama

Hatakeyama

Kato

et al. 2014

Biomed. Opt. Express

Self Cite

View full text Add to dashboard Cite

show abstract

“…Tumor cells were destroyed with no tumor regrowth observed after treatment, as no viable tumor cells were found. In a previous study14, we investigated photothermal therapy of tumors in LNs using near-infrared laser light and various types of AuNRs, including bare AuNRs, neutravidin polymer-conjugated AuNRs and fluorescent AuNRs conjugated with Atto 590-biotin. There were no significant differences in body weight and serum total bilirubin, alanine aminotransferase, aspartate aminotransferase and blood urea nitrogen between control mice and those administered AuNRs, suggesting no major systemic toxicity.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the emergence of photothermal therapy (PTT) as a minimally invasive therapeutic strategy has attracted interest in the field of nanoparticle-mediated cancer treatment. The local application of external near-infrared (NIR) laser radiation to nanoparticles causes strong light absorption and subsequent rapid and efficient conversion of photon energy into heat, leading to irreversible thermal damage to proteins and DNA13141516.…”

mentioning

confidence: 99%

A novel treatment for metastatic lymph nodes using lymphatic delivery and photothermal therapy

Oladipo

Oluwafemi

Songca

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

Systemic delivery of an anti-cancer agent often leads to only a small fraction of the administered dose accumulating in target sites. Delivering anti-cancer agents through the lymphatic network can achieve more efficient drug delivery for the treatment of lymph node metastasis. We show for the first time that polymeric gold nanorods (PAuNRs) can be delivered efficiently from an accessory axillary lymph node to a tumor-containing proper axillary lymph node, enabling effective treatment of lymph node metastasis. In a mouse model of metastasis, lymphatic spread of tumor was inhibited by lymphatic-delivered PAuNRs and near-infrared laser irradiation, with the skin temperature controlled by cooling. Unlike intravenous injection, lymphatic injection delivered PAuNRs at a high concentration within a short period. The results show that lymphatic administration has the potential to deliver anti-cancer agents to metastatic lymph nodes for inhibition of tumor growth and could be developed into a new therapeutic method.

show abstract

“…130,243,244 However, in the operative field, the contrast between lymph nodes and the surrounding tissue is often quite limited. 101 In another study, graphene oxide modified with iron oxide nanoparticles and PEG coating (GO-IONP-PEG) [248][249][250] was used by Wang et al to diagnose and treat tumor metastasis. In our recent study, single-walled carbon nanotubes (SWNTs) were utilized as a NIR photothermal agent as well as a NIR-II fluorescent probe (Fig.…”

Section: Nanoparticle-based Drug Delivery For Cancer Metastasis Treatmentioning

confidence: 99%

Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy

et al. 2016

View full text Add to dashboard Cite

Metastasis is directly or indirectly responsible for the majority of cancer deaths. Anti-metastasis treatment is thus the key to cure cancer. Recent development in nanomedicine has shown great promise for tackling cancer metastasis. In recent years, nanoparticle-based drug delivery systems have been extensively explored for improving cancer treatment, showing the ability to reduce the risk of tumor metastasis compared with conventional chemotherapy. Photothermal therapy, by employing nano-theranostic agents, has also been found to be able to inhibit lymphatic tumor metastasis. Moreover, the post-immunological effects of certain types of nano-therapies may also be utilized to treat tumor metastasis, presenting an exciting new avenue towards successful cancer treatment. In this review article, we would like to summarize the latest research advances in the development of various emerging nanomedicine approaches for cancer metastasis treatment, and discuss future prospects in this emerging field as well as the clinical translation potential of these techniques.

show abstract

Photothermal therapy of tumors in lymph nodes using gold nanorods and near-infrared laser light

Cited by 80 publications

References 24 publications

Visualization of fluid drainage pathways in lymphatic vessels and lymph nodes using a mouse model to test a lymphatic drug delivery system

Visualization of fluid drainage pathways in lymphatic vessels and lymph nodes using a mouse model to test a lymphatic drug delivery system

A novel treatment for metastatic lymph nodes using lymphatic delivery and photothermal therapy

Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy

Contact Info

Product

Resources

About